DARIC receptors incorporating the C2 epitope–specific VHH (DARIC-VHH1) displayed rapamycin-dependent recognition and activation against multiple gene-modified and AML cell lines, as well as an in vivo antitumor effect against established CD33+ human tumor xenografts in NSG mouse models. The gene discussed is CD33; the disease is neoplasm.